Oculis Holding AG (OCS) Revenue (2023)

Oculis Holding AG's (OCS) quarterly Revenue came in at -$6.9 million in Q4 2023.

Oculis Holding AG (OCS) Revenue (2023) Analysis & Trends

Oculis Holding AG's Revenue history runs 1 years deep, the most recent figure standing at -$6.9 million for Q4 2023.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Revenue (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn - -
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn 1.51 Bn
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn 2.99 Bn
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn 3.61 Bn
7 Belite Bio 61.40 Bn 61.40 Bn - -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn 1.30 Bn
9 Revolution Medicines 37.37 Bn 37.37 Bn - -
10 Alnylam Pharmaceuticals 36.08 Bn 33.07 Bn 959.66 Mn 1.17 Bn

Historic Data

Download Data
DateValue
Dec 31, 2023 -6.92 Mn